Results 191 to 200 of about 36,022 (296)

Molecular characterization of norovirus false-positive results on the BioFire FilmArray gastrointestinal panel. [PDF]

J Clin Microbiol
Reed JC, Mauer C, Mack AR, Theriault EA, Tansarli GS, Fang FC, Bourassa L, Greninger AL.   +7 more
europepmc   +1 more source

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10418-10427, November 2026.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice. [PDF]

Diabetes Obes Metab
Zhang Y, Zhu B, Peng B, Wu P, Zhong G, Wang Y, Wang Z, Feng X, Tang D, Peng D, Liu Y.   +10 more
europepmc   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review. [PDF]

Ther Adv Endocrinol Metab
Alawad AO, Merghani TH, Fadelelmoula TE, Elamin NA, Satti S, Edris AA, Hakim A, El-Hindi RF, Alhaj-Ali AA, Ibrahim WE, Mustafa MA, Sirelkhatim MM, Ahmed HH, Yousif NO.   +13 more
europepmc   +1 more source

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

Rise or fall? Reconciling contested directions in human gut hormone aging. [PDF]

Front Endocrinol (Lausanne)
Mavrych V, Shypilova I, Bolgova O.
europepmc   +1 more source

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9861-9870, November 2026.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels, C. R. Williams, M. B. Patel, W. H. Self, L. M. Funk, C. Roumie, M. D. Spann, C. J. Northup, F. Ye, R. Irlmeier, I. Sohn, Y. Zhu, K. Niswender   +12 more
wiley   +1 more source

The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice. [PDF]

Dermatol Ther (Heidelb)
Giorgio CM, Romanò C, Arisi M, Rossi M, Venturini M, Mezzana S, Grigolato L, Galli B, Nicoletti MM, Tomasi C, Licata G.   +10 more
europepmc   +1 more source